|
|
China Cosmetics Formula Ingredients Analysis System
|
|
All cosmetics need apply
CFDA register, after get the approval of
CFDA then can be imported to China; Only 50%~60% INCI (International Nomenclature Cosmetic Ingredient) cosmetics ingredients are permitted to use in China by
CFDA, if products formula contain incompliance ingredients, will cause the fail of
CFDA registration. |
China CFDA Cosmetics Prohibitted Ingredients Query
:A
CFDA No. |
Prohibitted Ingredient Name |
Ingredient Chinese Name |
246 |
A 2:1 mixture of: 4-(7-hydroxy-2,4,4-trimethyl-2-chromanyl)resorcinol-4-yl-tris(6-diazo- 5,6-dihydro-5-oxonaphthalen-1-sulfonate) and 4-(7-hydroxy-2,4,4-trimethyl-2-chromanyl) resorcinolbis(6-diazo-5,6-dihydro-5-oxonaphthalen-1-sulfonate) (CAS No. 140698- |
4-(7-羟基-2,4,4-三甲基-2-苯并二氢吡喃基)间苯二酚-4-基-三(6-重氮
基-5,6-二氢化-5-氧代萘-1-磺酸盐)和 4-(7-羟基-2,4,4-三甲基-2-苯并二 氢吡喃基)间苯二酚双(6-重氮基-5,6-二氢化-5-氧代萘-1-磺酸盐)的 2:1 混合物 |
247 |
A mixture of: 1,3,5-tris(3-aminomethylphenyl)-1,3,5-(1H,3H,5H)-triazine-2,4,6-trione and a mixture of oligomers of 3,5-bis(3-aminomethylphenyl)-1-poly(3,5-bis(3-aminomethylphenyl)
-2,4,6-trioxo-1,3,5-(1H,3H,5H)-triazin-1-yl)-1,3,5-(1H,3H,5H)-triazine-2,4, |
1,3,5-三(3-氨基甲基苯基)-1,3,5-(1H,3H,5H)-三嗪-2,4,6-三酮和 3,5-双
(3-氨基甲基苯基)-1-聚(3,5-双(3-氨基甲基苯基)-2,4,6-三氧代
-1,3,5-(1H,3H, 5H)-三嗪-1-基)-1,3,5-(1H,3H,5H)-三嗪-2,4,6-三酮混合
低聚物的混合物 |
248 |
A mixture of: 4-((bis-(4-Fluorophenyl)methylsilyl)methyl)-4H-1,2,4-triazole and 1-((bis-(4-fluorophenyl)methylsilyl)methyl)-1H-1,2,4-triazole(EC No. 403-250-2) |
4-((双-(4-氟苯基)甲基甲硅烷基)甲基)-4H-1,2,4-三唑和 1-((双-(4-氟苯 基)甲基甲硅烷基)甲基)-1H-1,2,4-三唑的混合物 |
249 |
A mixture of: 4-allyl-2,6-bis (2,3-epoxypropyl)phenol, |
下列化合物的混合物:4-烯丙基-2,6-双(2,3-环氧丙基)苯酚,4-烯丙基 |
250 |
A mixture of: 5-((4-((7-amino-1-hydroxy-3-sulfo-2-naphthyl) azo)-2,5-diethoxyphenyl)azo)-2
-((3-phosphonophenyl)azo)benzoic acid and 5-((4-((7-amino-1-hydroxy-3-sulfo-2-naphthyl)azo)- 2,5-diethoxyphenyl)azo)-3-((3-phosphonophenyl) azo)benzoic acid (CAS No |
5-((4-((7-氨基-1-羟基-3-硫代-2-萘基)偶氮)-2,5-二乙氧基苯基)偶
氮)-2-((3-膦酰基苯基)偶氮)苯甲酸和 5-((4-((7-氨基-1-羟基-3-硫代-2- 萘基)偶氮)-2,5-二乙氧基苯基)偶氮)-3-((3-膦酰基苯基)偶氮)苯甲酸的 混合物 |
251 |
A mixture of: disodium 4-(3-ethoxycarbonyl-4-(5-(3-ethoxycarbonyl-5-hydroxy-1-(4- |
4-(3-乙氧基羰基-4-(5-(3-乙氧基羰基-5-羟基-1-(4-磺酸基苯基)吡唑-4- |
252 |
A mixture of: N-(3-Hydroxy-2-(2-Methylacryloylaminomethoxy)propoxymethyl)-2-methylacrylamide and N-(2,3-bis-(2-Methylacryloylaminomethoxy)propoxymethyl)-2-methylacrylamide and methacrylamide and 2-methyl-N-(2-methylacryloylaminomethoxymethyl)-acrylamide a |
N-(3-羟基-2-(2-甲基丙烯酰氨基甲氧基)丙氧基甲基)-2-甲基丙烯酰胺 和 N-(2,3-双-(2-甲基丙烯酰氨基甲氧基)丙氧基甲基)-2-甲基丙烯酰胺 和甲基丙烯酰胺和 2-甲基-N-(2-甲基丙烯酰氨基甲氧基甲基)-丙烯酰 胺和 N-(2,3-二羟基丙氧基甲基)-2-甲基丙烯酰胺的混合物 |
253 |
A mixture of: reaction product of 4,4’-methylenebis(2-(4-hydroxybenzyl)-3,6-dimethylphenol) and 6- diazo-5,6-dihydro-5-oxo-naphthalenesulfonate(1:2) and reaction product of 4,4’-methylenebis (2-(4- hydroxybenzyl)-3,6-dimethylphenol) and 6-diazo-5,6-dihydr |
4,4’-亚甲基双(2-(4-羟基苄基)-3,6-二甲基苯酚)和 6-重氮基-5,6-二氢化
-5-氧代-萘磺酸盐的 1:2 反应产物及 4,4’-亚甲基双(2-(4-羟基苄基)-3,6- 二甲基苯酚)和 6-重氮基-5,6-二氢化-5-氧代萘磺酸盐的 1:3 反应产物 的混合物 |
254 |
Absorption oils, bicyclo arom and heterocylic hydrocarbon fraction (CAS No 101316-45-4), if they
contain> 0.005% (w/w) benzo[a]pyrene |
苯并[a]芘的含量大于 0.005%(w/w)的吸收油, 来自双环芳烃和杂环碳 氢化合物馏分 |
255 |
Acenocoumarol (INN) (CAS No. 152-72-7) |
醋硝香豆素 |
256 |
Acetamide (CAS No. 60-35-5) |
乙酰胺 |
257 |
Acetonitrile (CAS No. 75-05-8) |
乙腈 |
258 |
Acid Black 131 (CAS No. 12219-01-1)and its salts |
酸性黑 131 及其盐类 |
259 |
Acid Orange 24 (CI 20170) (CAS No. 1320-07-6) |
酸性橙 24(CI 20170) |
260 |
Acid Red 73 (CI 27290) (CAS No. 5413-75-2) |
酸性红 73(CI 27290) |
261 |
Aconitine (principal alkaloid of Aconitum napellus L.) (CAS No. 302-27-2)and its salts |
乌头碱(欧乌头主要生物碱)及其盐类 |
262 |
Acrylamide (CAS No. 79-06-1),unless regulated elsewhere in this Standard |
丙烯酰胺, 在本规范别处规定的除外 |
263 |
Acrylonitrile (CAS No. 107-13-1) |
丙烯腈 |
264 |
Alachlor (ISO) (CAS No. 15972-60-8) |
甲草胺(草不绿) |
265 |
Aldrin (ISO) (CAS No. 309-00-2) |
艾氏剂 |
Alphabet
Shortcut:
A
| B
| C
| D
| E
| F
| G
| H
| I
| G
| K
| L
| M
| N
| O
| P
| Q
| R
| S
| T
| U
| V
| W
| X
| Y
| Z
|
|
|
|
|
|
|